HOME >> BIOLOGY >> NEWS
Nature's path leads scientists to new antibiotic strategy

MADISON - By mimicking one of nature's own potent antimicrobial defenses, scientists may have found a new way to wage war on pathogenic bacteria.

Writing this week (April 6) in the British scientific journal Nature, a team of scientists from the University of Wisconsin-Madison report the design, synthesis and evaluation of a new type of molecule that exhibits a wide spectrum of antimicrobial activity, including against two species of bacteria that are resistant to common antibiotic drugs.

The work is important because it demonstrates the feasibility of developing a new class of antibiotics that can potentially overcome the growing resistance of disease-causing bacteria to current medicines, according to UW-Madison chemistry Professor Samuel H. Gellman, an author of the new study. Moreover, the work reveals the potential of using nature as a guide to build medically important synthetic molecules that can outperform their naturally-occurring counterparts.

"Nearly all antimicrobial agents now used in clinical settings are naturally-occurring molecules, or are closely related to molecules found in nature," Gellman said. "In contrast, our new antimicrobials are very different from all molecules found in nature. The upshot of this research is that we may be on a radical new path that may lead to the rational, deliberate design of clinically useful molecules like antibiotics."

The design of the new antibacterial agents involved mimicry of naturally-occurring peptides that ward off microbial invasion.

Peptides are composed of alpha-amino acids which also are the building blocks of protein molecules and are essential to all life. In nature, peptides can be selectively toxic to invading microorganisms, forming a first line of antimicrobial defense in everything from plants to people. The natural antibiotic peptides, however, are rapidly degraded in living tissues and can be highly toxic to human cells in addition to infectious
'"/>

Contact: Samuel H. Gellman
gellman@chem.wisc.edu
608-262-3303
University of Wisconsin-Madison
4-Apr-2000


Page: 1 2 3

Related biology news :

1. Natures ambush: pregnancy more likely from single unprotected intercourse than believed
2. Researchers discover structure of Natures circuit breaker
3. Natures own antidote to cocaine
4. Natures own medicine for vision loss: Inhibitor of angiogenesis found by biologists at The Scripps Research Institute
5. Natures chemical weapons save lives
6. Worlds Leading Echinacea Researchers To Examine Latest Scientific Findings On "Natures Gentle Antibiotic"
7. Natures Sugar High
8. Photosynthetic Harvest Inc. Harnesses The Power Of Natures Chemical Factories By "Milking" Green Plants For Valuable Natural Products
9. Loss of the neuronal adhesion protein d-catenin leads to severe cognitive dysfunction
10. Cockroach-like robot leads new research effort
11. Washington University in St. Louis leads group studying aging process

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Nature path leads scientists new antibiotic strategy

(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... Dec. 10, 2014  Data Sciences International (DSI), ... released a new series of digital telemetry implants ... researchers. M series, part of the PhysioTel™ Digital ... best possible physiologic data when incorporating functional endpoints ... endpoints to toxicology studies has evolved from short ...
(Date:12/10/2014)... DUBLIN , Dec. 08, 2014 Research ... announced the addition of the "Biometrics Market ... http://photos.prnewswire.com/prnh/20130307/600769 ... for projects such as rural banking and upgradation ... major trends witnessed in the market. Besides the ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
(Date:12/17/2014)... AUSTIN, Texas , Dec. 16, 2014  Vermillion, ... company focused on gynecologic disease, today announced the next ... into a premier bio-analytics solutions provider with the naming ... to President and Chief Executive Officer, while current Chairman ... will continue to serve as Chairman. These changes are ...
(Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
(Date:12/17/2014)...   Synageva BioPharma Corp. (NASDAQ: ... rare disorders, announced today its presentation at the upcoming ... San Francisco, CA. Sanj ... present on Monday, January 12, 2015, at 9:00 a.m. ... live and may be accessed from the "Webcasts & ...
(Date:12/15/2014)... YORK & PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI ), a leading developer ... today that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was ... Israel,s Office of the Chief Scientist ... been in receipt of grant support from the Office ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
Cached News: